

2019年 業績

I. 論文

1. 筆頭者が当科所属で主に当科で行われたもの

- 1) Shimomura Y, Sakai S, Ueda H, Fujikura K, Imai Y, Ishikawa T. Encapsulating peritoneal sclerosis in a patient after allogeneic hematopoietic stem cell transplantation: a case report. *BMC Gastroenterol.* 2019 Jan 21;19(1):12.
- 2) Ono Y, Yoshioka S, Inoue K, Yoshida M, Maruoka H, Ishikawa T. Stochastic model based on preharvest peripheral CD34-positive cell count and collection efficiency predicting processed blood volume in peripheral hematopoietic stem cell apheresis. *Transfusion.* 2019 Feb;59(2):671-680.
- 3) Yabushita T, Yoshioka S, Furumiya T, Nakamura M, Yamashita D, Imai Y, Ishikawa T. The impact of early diagnosis on the prognosis of extranodal NK/T-cell lymphoma with massive lung involvement: a case report. *BMC Pulm Med.* 2019 Feb 21;19(1):48.
- 4) Ogata T, Shimomura Y, Yamashita D, Imai Y, Ishikawa T. Substantial improvement in immune thrombocytopenic purpura associated with T-cell/histiocyte-rich B-cell lymphoma treated with chemotherapy: A case report. *Mol Clin Oncol.* 2019 Apr;10(4):441-445
- 5) Shimomura Y, Hara M, Tachibana T, Ohashi K, Sakura T, Fukuda T, Nakazawa H, Iwato K, Kanda Y, Ikeda T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Ishikawa T, Ishiyama K. Outcomes of second allogeneic haematopoietic stem cell transplantation in patients with relapse of myelodysplastic syndrome. *Br J Haematol.* 2019 Jul;186(1):86-90.
- 6) Morita-Fujita M, Katoh D, Shimomura Y, Ishikawa T. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study. *Clin Lymphoma Myeloma Leuk.* 2019 Jul;19(7):e337-e342.
- 7) Katoh D, Ochi Y, Hiramoto N, Morita M, Yabushita T, Shimomura Y, Yamashita D, Ono Y, Yoshioka S, Yonetani N, Matsushita A, Imai Y, Hashimoto H, Ishikawa T. Parvovirus B19 infection in adult patients after allogeneic stem cell transplantation: our experience of five cases and literature review. *Bone Marrow Transplant.* 2020 Mar;55(3):653-656.
- 8) Fujimoto A, Hiramoto N, Yamasaki S, Inamoto Y, Uchida N, Maeda T, Mori T, Kanda Y, Kondo T, Shiratori S, Miyakoshi S, Ishiyama K, Ikegame K, Matsushashi Y, Tanaka J, Ichinohe T, Atsuta Y, Ogata M, Suzuki R. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2019 Jul;25(7):1441-1449.
- 9) 中村 桃子, 吉岡 聡, 山下 大祐, 原 重雄, 石川 隆之 Ibrutinibにより自己免疫性血球減少症が改善した単クローン性免疫グロブリン沈着症合併慢性リンパ性白血病 臨床

血液 2019 年 60 卷 10 号 p. 1449-1454

- 10) 藤本 亜弓, 平本 展大, 松下 章子, 石川 隆之 Lenalidomide を含むレジメンが奏効した髄膜浸潤形質細胞性白血病 臨床血液 2019 年 60 卷 11 号 p. 1550-1554
2. 当科所属者が分担執筆者もしくは共同研究（下線が当科所属者）
 - 1) Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. Hematol Oncol. 2019 Feb;37(1):85-95.
 - 2) Wakamatsu M, Terakura S, Ohashi K, Fukuda T, Ozawa Y, Kanamori H, Sawa M, Uchida N, Ota S, Matsushita A, Kanda Y, Nakamae H, Ichinohe T, Kato K, Murata M, Atsuta Y, Teshima T. on behalf of the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors Blood Advances 2019 3:105-115
 - 3) Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Ohashi K, Fukuda T, Ozawa Y, Ota S, Uchida N, Eto T, Iwato K, Ohno Y, Takanashi M, Ichinohe T, Atsuta Y, Miyazaki Y. Clinical impact of the loss of chromosome 7q on outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 Sep;54(9):1471-1481.
 - 4) Itonaga H, Ishiyama K, Aoki K, Aoki J, Ishikawa T, Uchida N, Ohashi K, Ueda Y, Fukuda T, Sakura T, Ohno Y, Iwato K, Okumura H, Kondo T, Ichinohe T, Takanashi M, Atsuta Y, Miyazaki Y. Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome. Ann Hematol. 2019 Jun;98(6):1367-1381.
 - 5) Watatani Y, Sato Y, Miyoshi H, Sakamoto K, Nishida K, Gion Y, Nagata Y, Shiraishi Y, Chiba K, Tanaka H, Zhao L, Ochi Y, Takeuchi Y, Takeda J, Ueno H, Kogure Y, Shiozawa Y, Kakiuchi N, Yoshizato T, Nakagawa MM, Nanya Y, Yoshida K, Makishima H, Sanada M, Sakata-Yanagimoto M, Chiba S, Matsuoka R, Noguchi M, Hiramoto N, Ishikawa T, Kitagawa J, Nakamura N, Tsurumi H, Miyazaki T, Kito Y, Miyano S, Shimoda K, Takeuchi K, Ohshima K, Yoshino T, Ogawa S, Kataoka K. Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019 Dec;33(12):2867-2883.
 - 6) Fujikura K, Yamashita D, Sakamoto R, Ishikawa T, Chuang SS, Itoh T, Imai Y.

Intravascular NK/T-cell lymphoma: clinicopathological and integrated molecular analysis of two cases provides a clue to disease pathogenesis. *J Clin Pathol*. 2019 Sep;72(9):642-646.

- 7) Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. *J Clin Exp Hematop*. 2019;59(2):98-100.
- 8) Iida S, Watanabe T, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Tobinai K. Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study. *Cancer Sci*. 2019 Sep;110(9):2924-2932.
- 9) Kawabata H, Usuki K, Shindo-Ueda M, Kanda J, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, Kayano H, Shimbo K, Chiba S, Ishikawa T, Arima N, Nohgawa M, Miyazaki Y, Kurokawa M, Arai S, Mitani K, Takaori-Kondo A; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes. *Int J Hematol*. 2019 Nov;110(5):533-542.
- 10) Fujisaki T, Ishikawa T, Takamatsu H, Suzuki K, Min CK, Lee JH, Wang J, Carson R, Crist W, Qi M, Nagafuji K. Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial. *Ann Hematol*. 2019 Dec;98(12):2805-2814.
- 11) Izumi K, Kanda J, Nishikori M, Arai Y, Ishikawa T, Yoshioka S, Ueda Y, Maeda T, Yonezawa A, Anzai N, Moriguchi T, Imada K, Akasaka T, Nohgawa M, Itoh M, Aiba A, Tsunemine H, Watanabe M, Kondo T, Takaori-Kondo A. Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group. *Ann Hematol*. 2019 Dec;98(12):2815-2823.

3. 依頼原稿

- 1) 石川隆之 MDS の治療 本邦における治療の現状 メチル化阻害薬 日本臨床 77(9) 1512-1517, 2019

II. 学会発表 (筆頭著者が当科所属のもの)

- 1) 平本展大、山崎宏人、中邑幸伸、内田直之、村田誠、花本仁、衛藤徹也、高梨美乃子、一戸辰夫、熱田由子、鈴木律郎、森毅彦 成人再生不良性貧血に対する臍帯血移植の予後と指摘前処置の検討 第 41 回日本造血細胞移植学会総会
- 2) 中村 桃子, 山下 大祐, 原 重雄, 石川 隆之 ベネトラス後再発に対し、イブルチニブ、同種造血幹細胞移植をおこなった慢性リンパ性白血病 第 81 回日本血液学会総会

- 3) 井本 寛東, 下村 良充, 瀬尾 龍太郎, 石川 隆之 新規発症造血器腫瘍の ICU 入室後の予後因子 第 81 回日本血液学会総会
- 4) 上條 公守, 下村 良充, 石川 隆之 単一施設での HIV 関連リンパ腫 12 例の後方視的臨床研究 第 81 回日本血液学会総会
- 5) 井本寛東、吉岡聡、石川隆之 当院で経験した血管内大細胞型 B 細胞リンパ腫の 24 例 第 112 回近畿血液学地方会
- 6) 上條 公守, 下村 良充, 齋藤健貴、加藤まどか、吉岡聡、米谷昇、石川 隆之 dasatinib により bone marrow aplasia に至った慢性骨髄性白血病の 1 例 第 112 回近畿血液学地方会
- 7) 神田まどか、下村良充、石川隆之 当院での血栓性血小板減少性紫斑病(TTP)症例の検討 第 112 回近畿血液学地方会
- 8) 岡田直樹、平本展大、山下大祐、丸岡隼人、石川隆之 過粘稠度症候群を機に診断された、t(14:16):MAF 陽性 IgM- κ 型多発性骨髄腫の 1 例 第 112 回近畿血液学地方会
- 9) 越智達也、吉岡聡、石川隆之 BD 療法が奏功したネフローゼ症候群合併 Light chain proximal tubulopathy 第 112 回近畿血液学地方会
- 10) Yoshimitsu Shimomura, Masahiko Hara, Hisashi Yamamoto, Tatsuo Ichinohe, Takahiro Fukuda, Minoko Takanashi, Yoshiko Atsuta and Takayuki Ishikawa. Impact of Adding Melphalan to Fludarabine and a Myeloablative Dose of Intravenous Busulfan for Patients Who Received Allogeneic Hematopoietic Stem Cell Transplantation 61st Annual Meeting and Exposition of American Society of Hematology
- 11) Takuto Mori, Nobuhiro Hiramoto, Ryosuke Ueda, Yoshimitsu Shimomura, Satoshi Yoshioka and Takayuki Ishikawa Combination of a Cyclophosphamide–Total Body Irradiation Conditioning Regimen and Tacrolimus Plus Mycophenolate Mofetil for Gvhd Prophylaxis Is Associated with Higher HHV-6 Encephalitis Incidence after Cord Blood Transplantation 61st Annual Meeting and Exposition of American Society of Hematology
- 12) Hiroharu Imoto, Hiroyuki Matsui, Yasuyuki Arai, Tadakazu Kondo, Yasunori Ueda, Kazunori Imada, Takashi Akasaka, Akihito Yonezawa, Kazuhiro Yago, Takayuki Ishikawa and Akifumi Takaori-Kondo. Risk Factors and the Therapeutic Efficacy for Thrombotic Microangiopathy in Patients after Allogeneic Hematopoietic Stem Cell Transplantation – Results of the Multicenter Retrospective Cohort Study 61st Annual Meeting and Exposition of American Society of Hematology